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Epidermal growth factor (EGF) family ligands are de-
rived by proteolytic cleavage of the ectodomains of in-
tegral membrane precursors. Previously, we established
that tumor necrosis factor -converting enzyme (TACE/
ADAM17) is a physiologic transforming growth factor-
(TGF-) sheddase, and we also demonstrated enhanced
shedding of amphiregulin (AR) and heparin-binding
(HB)-EGF upon restoration of TACE activity in TACE-
deficient EC-2 fibroblasts. Here we extended these re-
sults by showing that purified soluble TACE cleaved
single sites in the juxtamembrane stalks of mouse pro-
HB-EGF and pro-AR ectodomains in vitro. For pro-HB-
EGF, this site matched the C terminus of the purified
human growth factor, and we speculate that the AR
cleavage site is also physiologically relevant. In con-
trast, ADAM9 and -10, both implicated in HB-EGF shed-
ding, failed to cleave the ectodomain or cleaved at a
nonphysiologic site, respectively. Cotransfection of
TACE in EC-2 cells enhanced phorbol myristate acetate-
induced but not constitutive shedding of epiregulin
and had no effect on betacellulin (BTC) processing.
Additionally, soluble TACE did not cleave the jux-
tamembrane stalks of either pro-BTC or pro-epiregulin
ectodomains in vitro. Substitution of the shorter pro-
BTC juxtamembrane stalk or truncation of the pro-
TGF- stalk to match the pro-BTC length reduced
TGF- shedding from transfected cells to background
levels, whereas substitution of the pro-BTC P2-P2 se-
quence reduced TGF- shedding less dramatically.
Conversely, substitution of the pro-TGF- stalk or
lengthening of the pro-BTC stalk, especially when com-
bined with substitution of the pro-TGF- P2–P2 se-
quence, markedly increased BTC shedding. These re-
sults indicate that efficient TACE cleavage is
determined by a combination of stalk length and scis-
sile bond sequence.
The epidermal growth factor (EGF)1 family includes seven
structurally related proteins as follows: EGF, transforming
growth factor- (TGF-), amphiregulin (AR), heparin-binding
epidermal growth factor (HB-EGF), betacellulin (BTC), epi-
regulin (EPR), and epigen (reviewed in Ref. 1). Members of this
family share a distinctive disulfide-bonded 3-loop domain, the
EGF-like motif, which is required for high affinity binding to
the EGF receptor (EGFR). Soluble receptor ligands containing
this EGF-like sequence are in each case released from integral
membrane precursor proteins. The critical “C-terminal” cleav-
age events that are required for release occur within short
juxtamembrane stalks that link the EGF-like motifs to the
transmembrane (TM) domains. Additionally, variable cleavage
at membrane distal sites (N-terminal cleavage) gives rise to
larger soluble forms and could modulate the function of EGF
family members. Whether both C- and N-terminal processing
events are mediated by the same or different enzymes is pres-
ently unclear.
Although both integral membrane and soluble growth fac-
tors have been shown to activate EGFR (2–5) with potentially
different consequences (6–9), the observed phenotypes of EGF
family knockouts are consistent with paracrine roles for these
growth factors (10–14), and some biological responses may be
impaired by preventing release of soluble growth factor (7,
15–18). Moreover, regulated shedding of EGF ligands has been
linked recently to G-protein-coupled receptor-mediated EGFR
transactivation (1, 19–24). Thus, identifying the mechanisms
that govern EGF family shedding is critical to an understand-
ing of the regulation of EGF family/EGFR action.
Several lines of evidence have implicated the disintegrin and
metalloprotease TACE/ADAM17 (25, 26) in the release of sol-
uble TGF-, a well studied model of ectodomain shedding. Mice
homozygous for a mutant TACE gene (TACEZn) encoding an
inactive enzyme displayed the same open eye at birth and wavy
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whisker (27) phenotype as TGF-- (10, 11) and EGFR-null
(28–30) mice. Fibroblasts, as well as primary keratinocytes,
derived from these TACE-deficient mice, were dramatically
impaired in their ability to shed TGF-, whereas restoration of
functional TACE enhanced processing (27, 31). Moreover, sol-
uble TACE correctly cleaved the pro-TGF- ectodomain at both
N- and C-terminal processing sites in vitro (31). Collectively,
these results established TACE as a major TGF- sheddase,
although TACE-deficient cells retain reduced ability to shed
TGF-, apparently because of the minor action of one or more
other metalloproteases (32, 33).
TACE-deficient mice die soon after birth, displaying epithe-
lial defects in lung, small intestine, stomach, thyroid, parathy-
roid, and salivary glands (27). These defects are broadly similar
to those observed in EGFR null mice, prompting speculation
that TACE is a Pan-EGF family sheddase (27, 34). Supporting
this notion, TACE-deficient and HB-EGF-null mice displayed
similarly defective cardiac valvulogenesis and poorly differen-
tiated lungs (14, 35), and cotransfection of TACE with pro-AR
and pro-HB-EGF increased the shedding of these growth fac-
tors from TACE-deficient fibroblasts (31). In addition, applica-
tion of TACE antisense oligonucleotides or small interfering
RNA diminished AR shedding from lung (36) and HNSCC cells
(24). Arguing against a role for TACE as a Pan-EGF family
convertase, EGF processing was shown to be metalloprotease-
dependent, but TACE-independent (37), and ADAM9 (38), -10
(23, 39), and -12 (21, 40) have all been implicated in HB-EGF
shedding in cell and animal models.
Here we used cell-based and in vitro assays to examine
further the role of TACE as a mediator of EGF family shedding.
Our results support recent genetic evidence implicating TACE
as a physiologic HB-EGF convertase, while arguing against
roles for ADAM9 and -10, and they are also consistent with
growing evidence that TACE is a major AR convertase. On the
other hand, although TACE contributed to PMA-induced shed-
ding of EPR, it did not affect constitutive release of either EPR
or BTC, nor did it efficiently cleave the ectodomains of pro-BTC
or pro-EPR in vitro. Through stalk domain swapping and mu-
tagenesis experiments aimed at understanding TACE prefer-
ence for pro-TGF- versus pro-BTC, we found that in addition
to scissile bond sequence, stalk length is a major determinant
of which EGF family precursors are efficient TACE substrates.
EXPERIMENTAL PROCEDURES
Materials—The antibodies used are as follows: monoclonal anti-HA.11
(Covance Research Products, Denver, PA), monoclonal anti-FLAG M2
(Sigma), polyclonal anti-human TGF- (Sigma), and polyclonal anti-
mouse BTC (R & D Systems, Minneapolis, MN). Peroxidase-conjugated
secondary antibodies were from Roche Applied Science or Santa Cruz
Biotechnology. The M2 monoclonal anti-FLAG affinity gel was obtained
from Sigma, and the anti-HA affinity resin and peptide were from
Roche Applied Science. Oligonucleotide primers were synthesized by
the University of North Carolina Lineberger Comprehensive Cancer
Center Nucleic Acids Core Facility. The QuickChange Site-directed
Mutagenesis kit (Stratagene, La Jolla, CA) was used to insert HA and
FLAG epitopes and to construct EGF family ectodomains and jux-
tamembrane domain mutants per the manufacturer’s instructions.
Construction of Epitope-tagged Growth Factors—Murine cDNAs for
the murine EGF ligands were epitope-tagged with HA and FLAG se-
quences (31, 41). Forward primers used for mutagenesis are as follows:
AR FLAG, 5-GGGACTGTGCACGCCGATTACAAGGACGACGATGA-
CAAGATTGCCTAG-3; HB-EGF FLAG, 5-GGGCGTGGCTAGCGATT-
ACAAGGACGACGATGACAAGTCCCACTGAGG-3; BTC HA, 5-CCT-
AGACAGAAAGTGAAAACCCACTACCCATACGACGTCCCAGACTA-
CGCTTTCTCTCGGTGCCCC-3; BTC FLAG, 5-CCATAAGTGAAGAT-
ATTCAAGAGACCAATGATTACAAGGACGACGATGACAAGATTGC-
TTAACGG-3; EPR HA,: 5-GGCTCAAGTGCAGATTTACCCATACGA-
CGTCCCAGACTACGCTACAAAGTGTAGTTCTGACATGG-3; and
EPR FLAG, 5-GGACCCAGTGCTGCCAGATTACAAGGACGACGAT-
GACAAGCAGGTCTGAAAGC-3. All cDNAs were expressed in pcDNA3
(Invitrogen), except pro-EPR, which was cloned into pSI (Promega Corp.,
Madison, WI) for optimal expression (42).
Transfection and Western Blot Analysis—EC-2 fibroblasts (43) were
grown in Dulbecco’s modified Eagle’s medium-F12 (DMEM/F-12) with
1% fetal bovine serum (FBS) and transfected in serum-free media with
the indicated cDNAs by using LipofectAMINE (Invitrogen). Chinese
hamster ovary (CHO) cells were grown in DMEM with 5% FBS and 1
nonessential amino acids and transfected by using FuGENE 6 (Roche
Applied Science). For TAPI-2 experiments, cells were switched to com-
plete media in the presence or absence of 50 M TAPI-2 (Peptides
International, Louisville, KY) after 24 h. After 24 h, conditioned media
and cell lysates were harvested. For PMA experiments, cells were
switched to complete media after 24 h. After 24 h, cells were washed
with serum-free media and incubated in serum-free media in the pres-
ence and absence of 100 ng/ml PMA (Sigma) for 2 h (43) before condi-
tioned media and cell lysates were harvested. For each PMA experi-
ment sample, media or lysate from three transfected 60-mm dishes
were pooled and treated together. All media was concentrated on Sep-
Pak C-18 cartridges (Waters) and lyophilized (44). To collect lysates,
cells were washed in 1 phosphate-buffered saline (PBS) and lysed in
50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100 with protease
inhibitors (10 g/ml leupeptin, 20 g/ml aprotinin, 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF), and 1 M EDTA). Protein concentrations
were determined by using the BCA Protein Assay (Pierce). Conditioned
media and cell lysates (75 g) were analyzed by Western blot (31)
as indicated.
Sandwich ELISA—To quantitate nanogram levels of epitope-tagged
growth factors, we developed a sandwich ELISA for TGF- and BTC
similarly to published protocols (45). Briefly, 96-well enzyme immuno-
assay/radioimmunoassay high binding plates (Corning Glass) were in-
cubated with 10–15 g/ml anti-HA overnight at room temperature.
After each incubation, wells were washed three times with wash buffer
(1 PBS, 0.05% Tween 20). Wells were blocked in 2% BSA, 1 PBS,
0.05% Tween 20 for 1 h at room temperature. Media and lysate samples
or standards (ligand ectodomains) were diluted in dilution buffer (2%
FBS, 1 PBS, 0.05% Tween 20), added to wells in triplicate, and
incubated for 1.5 h at room temperature. Anti-growth factor antibodies
diluted 1:100 (anti-TGF-) or 1:200 (anti-BTC) in dilution buffer were
added for 1.5 h at room temperature. Anti-goat horseradish peroxidase
(Santa Cruz Biotechnology) diluted 1:10,000 in dilution buffer was
added for 1 h at room temperature. Color substrate solution (R & D
Systems, Minneapolis, MN) was added to wells and incubated for 20
min at room temperature in the dark. The color reaction was stopped by
adding 1.5 N sulfuric acid and immediately read on a plate reader at 450
nm.
Production of Ectodomain Ligands—Pro-TGF-ecto was generated







To produce ectodomain proteins, cDNAs were transfected into COS-1
cells using FuGENE 6 (Roche Applied Science). After 24 h, cells were
placed in complete media (DMEM, 10% FBS) and cultured for an
additional 24 h before conditioned media were collected. For pro-BT-
Cecto and pro-EPRecto, conditioned media were concentrated as before
(31). For pro-ARecto and pro-HB-EGFecto, media were immunoprecipi-
tated by using anti-HA affinity resin at 4 °C with tumbling for 24–48 h.
Beads were washed with 20 bed volumes of wash buffer (20 mM Tris, pH
7.5, 0.1 M NaCl, 0.1 mM EDTA, 0.05% Tween 20), and bound proteins
were eluted by using 1 mg of HA peptide in equilibration buffer (20 mM
Tris, pH 7.5, 0.1 M NaCl, 0.1 mM EDTA) at 37 °C with tumbling. To
remove excess HA peptide, proteins were dialyzed against 10 mM Tris,
pH 8.0, at 4 °C for 16–18 h using Spectra-Por membrane (10,000 mo-
lecular weight cut-off) (Spectrum Laboratories Inc., Rancho Dominguez,
CA). The protein concentrations were assayed using the BCA Protein
Assay (Pierce) and normalized for ectodomain proteins by comparison
on Western blots.
In Vitro Digests—Aliquots (1–10 g) of ectodomain proteins were
incubated with 150–300 g/ml recombinant human TACE or ADAM9
or ADAM10 (R & D Systems) or 10 mM Tris, pH 8.0 (as indicated) (31),
for 1 or 24 h. Reactions were stopped by adding SDS-PAGE sample
buffer, and products were separated by SDS-PAGE, transferred to
Immobilon polyvinylidene difluoride, and probed with the indicated
antibodies. For determination of N- and C-terminal cleavage sites,
reactions were stopped by adding 10 mM EDTA, and products were
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immunoprecipitated by using M2 anti-FLAG affinity gel at 4 °C for
16–18 h. Beads were washed five times with fresh 50 mM ammonium
bicarbonate. Molecular weights of cleavage products were determined
by matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI/TOF-MS) using a Bruker Reflex III mass spectrom-
eter (Bruker Instruments Co., Billerica, MA) optimized in the linear
mode (46, 47), and recrystallized -cyano-4-hydroxycinnamic acid (Al-
drich) was used as the matrix. The -cyano-4-hydroxycinnamic acid
solvent was 50:50:0.1 acetonitrile/water/trifluoroacetic acid and used as
a saturated solution. A 0.5-l aliquot of the settled beads was spotted on
the target, followed by 0.5 l of matrix solution, and the solution was
allowed to dry at room temperature.
Construction of Juxtamembrane Domain Mutants—Epitope-tagged
pro-TGF- (41) and pro-BTC cDNAs were used to construct juxtamem-
brane domain mutants. For the BTC-JMFYLQ-LAVV2 mutant, sequential
rounds of mutagenesis were performed using the BTC-JMFYLQ-LAVV and








AAGCAAATCCTGGTGGTCTGC-3; and BTC-JMFYLQ-LAVV, 5-GGTGT-
GAGCGAGTGGACCTGCTTGCCGTCGTGCAGGACCGGGG G-3.
Statistical Analysis—Statistical analysis was performed by the Uni-
versity of North Carolina Lineberger Comprehensive Cancer Center
Biostatistics Facility using SAS statistical software, version 8.2 (SAS
Institute Inc., Cary, NC), and the Wilcoxon rank sum test for pairwise
group comparisons. p values are exact and have been adjusted by using
the Bonferroni method to allow multiple comparisons.
RESULTS
TACE Does Not Enhance Shedding of Betacellulin or Epi-
regulin from Cells—We showed previously that cotransfection
of TACE with TGF-, AR, or HB-EGF enhanced shedding of
these growth factors from TACE-deficient (EC-2) fibroblasts
(31). To assess the role of TACE in the shedding of two addi-
tional EGF family members, BTC and EPR, we generated
epitope-tagged constructs encoding the precursors (Fig. 1A). As
with pro-TGF- (41), the HA epitope was inserted into the
N-terminal portion of the EGF-like sequence, either three
(BTC) or two (EPR) amino acids upstream of the first cysteine.
In both cases, the FLAG epitope was inserted into the cytoplas-
mic domain of the precursor immediately preceding the penul-
timate amino acid. Tagged pro-BTC or pro-EPR were trans-
fected into EC-2 fibroblasts, which lack functional TACE (43),
in the presence or absence of TACE cDNA, and lysates and
conditioned media were analyzed by Western blot by using HA
and FLAG antibodies. Pro-TGF- and empty pcDNA3 vector
were transfected as positive and negative controls.
As observed previously (31), lysates of TGF--transfected
EC-2 cells (43) contained 36- and 20–25-kDa species that were
recognized by both anti-HA (Fig. 2A) and anti-FLAG (data not
shown); the 36-kDa form is the fully glycosylated precursor,
and the 20–25-kDa forms are immature glycoprotein precur-
sors (41). FLAG, but not HA antibody, also recognized a minor
16-kDa species corresponding to the residual transmembrane
(TM)/cytoplasmic domains of pro-TGF- (Fig. 2A). Media from
the transfected cells contained low levels of soluble HA-reactive
6- and 25-kDa proteins corresponding to mature TGF- and
larger fully glycosylated forms cleaved only at the C-terminal
site (48). High speed centrifugation of conditioned media con-
firmed that the 25-kDa protein was soluble and not membrane-
associated (data not shown). In some experiments, the species
appeared as closely spaced doublets. Inclusion of the metallo-
protease inhibitor, TAPI-2, in the culture increased levels of
the precursor forms (Fig. 2A), decreased the 16-kDa tail, and
shifted media forms to higher molecular weight, implicating
metalloproteases in residual pro-TGF- processing in EC-2
cells. As observed previously (31), cotransfection of TACE de-
creased the 36-kDa proform, dramatically increased levels of
the 16-kDa, FLAG-reactive residual cytoplasmic tail (Fig. 2A),
and increased levels of both the soluble 6- and 25-kDa growth
factors. An ELISA confirmed the large (17-fold) TAPI-inhib-
itable increase in media TGF- seen in Fig. 2A when cells were
cotransfected with TGF- and TACE as compared with cells
transfected with TGF- alone (data not shown).
Transfection of the pro-BTC cDNA into EC-2 fibroblasts pro-
duced several forms of cell-associated BTC, including promi-
nent species of 36 and 42 kDa that were recognized by anti-
HA (Fig. 2A) and anti-FLAG (data not shown). These likely
correspond to variably glycosylated full-length forms, because
murine BTC has three N-glycosylation sites (49). An 18-kDa
protein recognized only by anti-FLAG (Fig. 2A) likely corre-
sponds to the residual TM/cytoplasmic domains (50). Media
contained several HA-reactive species ranging from 32 to 36
kDa, close to the size reported for purified mouse BTC (49).
TAPI-2 treatment led to accumulation of the larger BTC forms
in cell lysate and diminished the levels of 18-kDa tail as well as
the soluble media proteins (Fig. 2A). In contrast to results with
pro-TGF-, cotransfection of TACE did not affect the relative
levels of the variously sized BTC proteins present in EC-2
lysates or media, although it did produce a minor new species
of 20 kDa (Fig. 2A), which may correspond to a previously
identified N-terminal cleavage product observed in transfected
CHO and MCF-7 cells (50).
Transfection of the pro-EPR cDNA alone produced cell-asso-
ciated proteins of 20, 38, and 40 kDa that were recognized by
both anti-HA (Fig. 2A, lane 1, EPR) and anti-FLAG (data not
shown). Identification of the 20-kDa form (Fig. 2A) as an N-
terminally processed EPR (42) is consistent with the selective
loss of this HA- and FLAG-reactive species in lysates from
TAPI-2-treated cells. FLAG, but not HA antibody, additionally
recognized a 17-kDa protein presumably corresponding to the
residual TM/cytoplasmic domains (Fig. 2A). The sizes of the
various products are consistent with a previous report (42).
Media from EPR-transfected cells contained low levels of an
FIG. 1. Constructs used in this study. A, representative schematic
of full-length epitope-tagged EGF family members (signal peptides not
shown). The abbreviations used are as follows: Pro, prodomain; JM,
juxtamembrane stalk. The EGF-like sequence is denoted by the black
box. *, an N-terminal extension, indicated by the hatched box, is present
in pro-AR, pro-BTC, and pro-HB-EGF; and N-terminal (N-term) cleav-
age occurs at various sites (dashed arrows). C-terminal (C-term) cleav-
age site is indicated by a solid arrow, and the residual tail (TM/
cytoplasmic domains) is indicated by a bracket. The locations of the HA
and FLAG tags are indicated. B, representative schematic of epitope-
tagged ectodomain constructs. The FLAG epitope is followed in each
case by the two C-terminal amino acids from the cytoplasmic domain of
the precursor (31).
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HA-reactive, 6-kDa protein that is consistent in size with the
purified mouse growth factor (51). TAPI-2 treatment reduced
the levels of this soluble protein (Fig. 2A). Most important,
cotransfection of TACE reduced the levels of intact pro-EPR
species but had no effect on levels of the 20- or 17-kDa cell-
associated or 6-kDa soluble products (Fig. 2A).
Collectively, these results implicate a metalloprotease other
than TACE in constitutive C-terminal BTC and EPR cleavage,
but leave open the possibility that TACE contributes to the
N-terminal processing of the respective precursors.
PMA-induced EPR Shedding Is TACE-dependent—Although
TACE did not affect constitutive shedding of BTC or EPR from
EC-2 cells, it could have a role in the regulated shedding of
these growth factors. To assess this possibility, transfected
EC-2 fibroblasts were incubated with 100 ng/ml PMA for 2 h
prior to harvesting media and cell lysates. PMA increased
media TGF- levels in cultures cotransfected with TGF- and
TACE as compared with untreated cultures (Fig. 2B). In con-
trast, PMA did not affect the levels of media BTC shed from
cells cotransfected with TACE (Fig. 2B), which is consistent
with a previous report (50) that PMA did not stimulate BTC
processing. However, PMA markedly increased the levels of
media EPR shed from cells cotransfected with TACE (Fig. 2B),
indicating that TACE may have a role in PMA-induced shed-
ding of EPR.
TACE Cleaves HB-EGF and AR Ectodomains in Vitro—We
confirmed previously that TACE correctly cleaved both the N-
and C-terminal processing sites of pro-TGF- in vitro (31). Here
we examined the ability of recombinant, soluble TACE to
cleave directly the ectodomains of other EGF family precursors.
As with pro-TGF-ecto (31), the constructs used encoded ectodo-
mains truncated immediately prior to the transmembrane do-
main (Fig. 1B). HA epitopes were incorporated into the mature
growth factor sequences as with the full-length precursors (31,
41), whereas FLAG epitopes were incorporated at the new C
termini. These constructs were transiently transfected into
COS-1 cells, and the soluble ectodomains were harvested from
conditioned media as described under “Experimental Proce-
dures.” Correct folding of the mature EGF-like sequence was
confirmed for each ectodomain by demonstrating that condi-
tioned media activated EGFR in a dose-dependent fashion
when added to receptor-positive cells (52) (data not shown).
To assess cleavage in vitro, ectodomains were incubated in
buffer or buffer containing TACE at concentrations of either
150 (AR, HB-EGF) or 300 g/ml (BTC, EPR) from 0 to 24 h at
37 °C. Products were then resolved by SDS-PAGE and probed
with anti-HA or anti-FLAG (Fig. 3). In the absence of TACE,
pro-ARecto migrated as a heterogeneous 31-kDa species. Addi-
tion of TACE rapidly converted this otherwise stable protein to
persistent species of 17–20 kDa that were recognized by both
anti-HA and anti-FLAG and therefore corresponded to N-ter-
minal cleavage products (Fig. 3). In contrast, a novel species of
12 kDa accumulated more slowly and was recognized only
by anti-HA; this product likely corresponded to a C-terminal
cleavage event (Fig. 3). These results suggest that TACE is
capable of cleaving both N- and C-terminal sites in the pro-
AR ectodomain.
To identify the critical site of C-terminal cleavage, we incu-
bated the reaction products with anti-FLAG beads to capture
the short C-terminal product generated by TACE cleavage (not
FIG. 2. Shedding of BTC and EPR is
not enhanced by cotransfection of
TACE in EC-2 fibroblasts. EC-2 fibro-
blasts (43) were transiently transfected
with epitope-tagged murine TGF-, BTC,
or EPR cDNAs alone or together with mu-
rine TACE cDNA in equal amounts as
indicated. A, after 24 h, cells were
switched into conditioning media contain-
ing or lacking TAPI-2 (50 M). After an
additional 24 h, cell lysates and media
were harvested for Western blot analysis
using the HA and FLAG antibodies. Con-
trol samples from cells transfected with
pcDNA3 are shown on the far left. Ap-
proximate molecular weights are indi-
cated. B, after 48 h, transfected cells were
switched into serum-free media contain-
ing or lacking PMA (100 ng/ml). After 2 h,
media from three identical plates for each
sample were harvested and pooled for
Western blot analysis by using the HA
antibody.
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visible by SDS-PAGE) (31, 33, 46). A unique TACE-dependent
peak of m/z 2453.3 was identified, and the isotopic expansion of
this peak confirmed its peptide origin (Fig. 4B, inset). This peak
represented cleavage of pro-AR at 176EKSMK2THSED185
(Fig. 4A), which is three amino acids downstream from the C
terminus of the human protein purified from TPA-stimulated
cells (K2S) (53). MALDI-TOF/MS analysis of the larger prod-
ucts present in the digests yielded modest, but reproducible,
peaks of m/z 12,963 and 14,872 (data not shown), which
respectively represented the N-terminal cleavage at
78EEYDN2EPQIS87 and 95VRVEQ2VIKPK104 and could
have produced the 20- and 17-kDa products observed in Fig. 3.
Two alternative human N-terminal cleavage sites have been
identified, 96YIVDD2SVRVE105 and 102VRVEQ2VVKPP111
(53). Thus, the TACE-dependent 99Q2V100 cleavage product
matched the shorter human AR form.
Heterogeneous pro-HB-EGFecto species were observed in
the absence of TACE, with predominant forms ranging from 25
to 30 kDa. TACE rapidly converted the larger ectodomain
species to two products of 16 and 17 kDa that were recognized
by both anti-HA and anti-FLAG (Fig. 3), and thus derived from
N-terminal cleavage. Although low levels of the 16-kDa prod-
uct were present prior to incubation, they increased only
slightly in the absence of added enzyme. Additionally, products
of 8 and 9 kDa accumulated in the presence of TACE, were
recognized only by anti-HA, and thus judged to be C-terminal
cleavage products (Fig. 3).
Direct MALDI/TOF analysis of 24-h HB-EGF digestion
products bound to anti-FLAG beads revealed a TACE-de-
pendent product of m/z 2570.1, representing cleavage at
145GLTLP2VENPL154 (Fig. 4) and matching precisely the C
terminus of the purified human protein (54). Thus, the 8- and
9-kDa products observed on SDS-PAGE (Fig. 3) likely had the
same C terminus but different N termini (corresponding to the
16- and 17-kDa products). Direct MALDI-TOF/MS analysis of
the 1-h digestion products identified a TACE-dependent prod-
uct of m/z 16,209 (data not shown), corresponding to N-termi-
nal cleavage at 29LRRGL2AAATS38. Cleavage at this site
would be expected to generate an N-terminal HA- and FLAG-
reactive protein of 16 kDa. The N terminus of mouse HB-EGF
has not been identified, but the human protein has multiple N
termini (31R2G32; 62R2D63; 72L2R73; 73R2V74) (55–58). The
TACE cleavage site identified here occurs 2 amino acids C-
terminal of the 31R2G32 site.
Because ADAM9 (38) and -10 have been implicated as pro-
HB-EGF convertases (23, 39), we tested their ability to cleave
pro-HB-EGFecto in vitro. ADAM9, at a concentration of 150
g/ml, did not cleave pro-HB-EGFecto (data not shown).
ADAM10 converted pro-HB-EGFecto to HA- and FLAG-reac-
tive 15- and 16.4-kDa N-terminal cleavage products, slightly
smaller than those observed with TACE (Fig. 3). No HA-only
reactive products corresponding to C-terminal cleavage were
observed. Despite lack of a detectable band on SDS-PAGE, we
analyzed 24-h total digestion products bound to anti-FLAG
beads by MALDI-TOF/MS and identified a single ADAM10
C-terminal cleavage site at 151ENPLY2TYDHT160 (data not
shown); this site is downstream from the C terminus of human
HB-EGF and, by comparison to the cleavage sites of other EGF
family precursors, likely is too close to the membrane to rep-
resent a physiologic cleavage site. Direct analysis of 1-h diges-
tion products identified a single ADAM10 N-terminal cleavage
site of 85TPSKE2RNGKK94 as well (data not shown), which
did not correspond to any of the known N termini of the
human protein.
In the absence of TACE, heterogeneous BTCecto species of
26 kDa were observed (Fig. 3). Low levels of a 9-kDa species
accumulated when incubated with a concentration of TACE
twice that used for AR or HB-EGF (300 versus 150 g/ml; no
products were observed with the lower concentration). The
9-kDa species was recognized by both anti-HA and anti-FLAG
and hence derived from N-terminal cleavage (Fig. 3). No HA-
only reactive products indicative of C-terminal cleavage were
observed. Similarly, heterogeneous higher molecular weight
pro-EPRecto species were converted to an HA/FLAG-reactive
9-kDa product in the presence of 300 g/ml TACE (data not
shown), and no C-terminal cleavage products were observed.
Because of the low levels of the 9-kDa BTC and EPR prod-
ucts, we were unable to identify the corresponding N-terminal
cleavage sites by MALDI-TOF/MS (Fig. 4 and data not shown).
TACE-dependent Cleavage Is Determined by the Juxtamem-
brane Domain—Our results indicate that TACE is not an effi-
cient C-terminal convertase for pro-BTC or pro-EPR either in
cell culture or in vitro. To gain insights into the primary se-
quence features that determine which EGF family precursors
are efficient TACE substrates, we aligned the juxtamembrane
domains of the EGF ligands. In addition to sequence differ-
ences at the scissile bond, the juxtamembrane stalks of pro-
BTC and pro-EPR are shorter when compared with pro-TGF-
(14 and 15 amino acids, respectively versus 16 amino acids)
(Fig. 5).
To assess whether these differences in sequence and stalk
length affect TACE cleavage, we created a series of pro-TGF-
mutants differing with respect to stalk features, and we com-
pared their processing to wild-type TGF- in transfected
TACE-positive (25) CHO cells. As shown in Fig. 6A, the native
stalk of pro-TGF- was replaced with the counterpart sequence
from BTC in TGF-JMBTC. For TGF-JM2, the two terminal
amino acids were truncated from the pro-TGF- stalk to model
the BTC stalk length. For TGF-JMLAVV-FYLQ, the P2–P2 cleav-
age site amino acids of TGF- (LAVV) were replaced with those
of BTC (FYLQ) (Fig. 6A). Fig. 6B confirms that these epitope-
FIG. 3. Cleavage of EGF ligand ectodomains. Ectodomains were
prepared as described under “Experimental Procedures” and incubated
in the presence and absence of recombinant human TACE (150 g/ml:
AR, HB-EGF; 300 g/ml: BTC, EPR) for 0–24 h. pro-HB-EGFecto was
also incubated with recombinant human ADAM10 (150 g/ml) for 0–24
h. Reactions were stopped by the addition of SDS-PAGE sample buffer
and analyzed by Western blot analysis using the HA and FLAG
antibodies.
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tagged mutant proteins were comparably expressed in CHO
cells. Additionally biotinylation experiments confirmed cell
surface expression in each case (data not shown).
A TGF--specific ELISA revealed that shedding of TGF-
proteins was reduced to near background levels when cells
expressed either of the truncated mutants, TGF-JMBTC or
TGF-JM2 (Fig. 6C, adjusted exact p values  0.007).
Shedding was also drastically decreased in the case of TGF-
JMLAVV-FYLQ, although in other experiments shedding was
reduced only 2-fold by this substitution of the BTC P2–P2
recognition site (data not shown).
To confirm the roles of these sequences, we created the
corresponding epitope-tagged pro-BTC mutants (Fig. 7A), and
we observed analogous results. We confirmed expression and
cell surface biotinylation of each protein (data not shown), but
we analyzed these mutant proteins by an HA/BTC sandwich
ELISA. Most interesting, CHO cells did not shed substantial
levels of transfected WT-BTC (Fig. 7B), but media BTC was
readily detected when CHO cells expressed the BTC mutant
containing the TGF- juxtamembrane stalk (BTC-JMTGF)
(Fig. 7B, adjusted exact p values  0.009). Although lengthen-
ing the BTC stalk by two residues (BTC-JM2) had only a
modest effect on shedding and replacement of the P2–P2 se-
quence (BTC-JMFYLQ-LAVV) had no discernible effect, combin-
ing these changes (BTC-JMFYLQ-LAVV2) dramatically en-
hanced shedding (Fig. 7B). Collectively, these data indicate
that stalk length is a major determinant of efficient TACE-
mediated cleavage and that the small apolar residues of the
pro-TGF- cleavage site are preferred. Additionally, the BTC
results suggest that stalk conformation may also have an in-
fluence on shedding.
DISCUSSION
Identification of the metalloproteases responsible for shed-
ding EGF family growth factors has received considerable at-
tention recently, particularly due to the importance of these
enzymes in regulating EGFR signaling, including via GPCR
transactivation. We and others (27, 31) have previously iden-
tified TACE as a major TGF- convertase on the basis of
genetic, cell biologic, and biochemical evidence. Here we extend
previous findings to support identification of TACE as an AR
and HB-EGF convertase. In contrast, our findings do not sup-
port a role for TACE in the shedding of BTC or in the consti-
tutive release of EPR. However, TACE could have a role in
regulated, PMA-inducible EPR shedding. While this paper was
being reviewed, Sahin et al. (59) described evidence from stud-
ies of ADAM9, -12, -15, and TACE knockout cells that sup-
ported a role for TACE as a key mediator of both constitutive
and PMA-regulated shedding of TGF-, AR, HB-EGF, and EPR
but not BTC or EGF. Thus, our results are in general agree-
ment with their findings but differ with respect to a positive
role for TACE in constitutive EPR shedding. Conceivably, this
contradiction could be due to differences in cell populations
assayed or used by Sahin et al. (59) of an AP-EPR chimeric
reporter.
The finding that TACE cleaved the C-terminal juxtamem-
brane stalk of pro-ARecto in vitro (Fig. 3) extends our previous
report (31) that cotransfection of TACE promoted AR shedding
from EC-2 cells and is consistent with results from several
laboratories, including a recent report (59) demonstrating re-
duced AR shedding from primary TACEZn/Zn fibroblasts. For
example, antisense oligonucleotides to TACE but not ADAM9
or -10 blocked AR shedding and EGFR transactivation trig-
gered by smoke-induced oxygen free radicals (36). Inhibition of
TACE by RNA interference or expression of a dominant/nega-
tive enzyme also suppressed GPCR-stimulated AR release and
EGFR signaling in squamous carcinoma cells (24). Recently, we
found that mammary gland rudiments from TACE-deficient
fetuses display impaired ductal outgrowth when transplanted
into nude mice.2 A similar defect was observed upon transplan-
tation of EGFR null mammary rudiments (60), and ductal
development was stunted in pubescent female mice lacking AR
2 M. D. Sternlicht, S. W. Sunnarborg, D. C. Lee, and Z. Werb, unpub-
lished observations.
FIG. 4. MALDI-TOF/MS determina-
tion of TACE C-terminal cleavage
sites. A, the juxtamembrane stalks of
mouse pro-ARecto and pro-HB-EGFecto.
The last cysteine of the EGF-like domain
is indicated by an asterisk, and the loca-
tion of the TM domain is indicated by the
box. Arrows denote the TACE cleavage
sites, numbered according to the prepro-
protein, beginning with the methionine of
the signal peptide. B, C-terminal cleavage
products determined by MALDI-TOF/MS.
Samples shown were incubated in the ab-
sence or presence of recombinant human
TACE for 24 h as shown in Fig. 3. Reac-
tions were stopped by the addition of 10
M EDTA to cleavage products bound to
FLAG-affinity resin (Sigma) and spotted
directly onto the MALDI target. Spectra
above are from samples incubated with-
out TACE, those below in the presence of
TACE. Insets show the isotopic expansion
of the indicated product peak.
FIG. 5. Alignment of the EGF ligand juxtamembrane domains.
Sequences of the juxtamembrane stalks aligned beginning with the last
cysteine of the EGF-like domain (*). The termini identified in the
purified, soluble mouse (TGF-, BTC, EPR) or human (AR, HB-EGF)
proteins are indicated with arrows. The TM domain is indicated.
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(12). Thus, the present findings add to a growing body of
evidence implicating TACE as a major mediator of AR-induced
biological responses.
On the other hand, the C-terminal site cleaved by TACE in
vitro (Fig. 4) did not match the C terminus of the soluble
human AR protein (183E2K184) purified from TPA-treated
MCF-7 cell media by Shoyab et al. (61), which was only three
amino acids downstream from the terminal Cys of the EGF-like
motif. However, it has been suggested by others that this is not
the bona fide C terminus of naturally secreted AR protein,
because this form is much less potent with respect to EGFR
activation and mitogenicity compared with recombinant AR
proteins containing C-terminal extensions (62, 63). In particu-
lar, a recombinant AR containing three additional amino acids,
which corresponds precisely to the form predicted from the in
vitro TACE cleavage site, possessed 40-fold higher EGFR
binding and mitogenic activities compared with the truncated
183E2K184 protein, and it corresponded closely to the respec-
tive activities of MCF-7 conditioned media (62). A soluble AR
species, inconsistent in size with a C terminus of 183E2K184,
was released from Madin-Darby canine kidney cells, suggest-
ing that AR is cleaved more distally to the EGF-like domain
(64). Moreover, the 183E2K184 position places cleavage closer
to the EGF-like motif and further from the cell membrane than
is observed with other EGF family ligands (Fig. 5). Thus, we
propose that the site cleaved by TACE in vitro (mouse
180K2T181; equivalent to human 187K2T188) is physiologically
relevant.
HB-EGF shedding has been the focus of considerable atten-
tion, due in part to its role in GPCR-induced EGFR transacti-
vation as well as interest in the potential juxtacrine roles of
pro-HB-EGF. However, the identity of the HB-EGF convertase
has been controversial. Our previous findings indicate that
TACE is an important physiologic regulator of HB-EGF shed-
ding. HB-EGF knockout and TACE-deficient mice displayed
indistinguishable cardiac valve and lung development defects
(14, 35), and cotransfected TACE promoted shedding of HB-
EGF from TACE-deficient cells (31). Moreover, HB-EGF shed-
ding from primary fibroblasts was impaired in TACE-deficient
cells (59). Here we additionally show that TACE cleaved pro-
HB-EGFecto in vitro at a site in the juxtamembrane domain
(Figs. 3 and 4) corresponding to the C terminus of the HB-EGF
protein purified from TPA-stimulated Vero-H cells (54).
Other metalloproteases, including ADAM9, -10, and -12,
have also been proposed as candidate HB-EGF convertases.
FIG. 6. TGF- juxtamembrane stalk mutations. A, TGF- jux-
tamembrane stalk mutants. The terminal cysteine of the EGF-like
domain is indicated (*), and the C-terminal cleavage site of wild-type
(WT) pro-TGF- (WT-TGF-) is indicated by an arrow. B, expression of
juxtamembrane domain mutants in CHO cells. CHO cells were tran-
siently transfected with pcDNA3 vector or juxtamembrane domain
mutants, and 24 h later, cells were switched to conditioning media.
After an additional 24 h, lysates were harvested for Western blot
analysis using the HA antibody. Note that CHO cells have been shown
previously to express different molecular weight forms of TGF- (80)
compared with EC-2 cells (31). C, shedding of TGF- juxtamembrane
stalk mutants is impaired. CHO cells were transiently transfected with
pcDNA3 vector or the juxtamembrane domain mutants. Twenty-four
hours following transfection, cells were switched to conditioning media.
After an additional 24 h, media and lysates were harvested and ana-
lyzed by sandwich ELISA by using the HA and TGF- antibodies.
Results are expressed as the ratio of media to lysate TGF- and repre-
sent two separate experiments analyzed in triplicate. The gray line
represents the median.
FIG. 7. BTC juxtamembrane stalk mutations. A, BTC juxtamem-
brane domain mutants. The terminal cysteine of the EGF-like domain
is indicated (*), and the C terminus of purified, soluble mouse BTC is
indicated by an arrow. B, sandwich ELISA of conditioned media and
lysates. CHO cells were transiently transfected with wild-type (WT) or
mutant proteins, and 24 h later, cells were switched to conditioning
media. After an additional 24 h, media and lysates were harvested and
analyzed by sandwich ELISA by using the HA and BTC antibodies.
Results are presented as the ratio of media to lysate-tagged BTC and
represent two separate experiments analyzed in triplicate. The gray
line represents the median.
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Dominant negative ADAM9 (MDC9/meltrin-) inhibited stim-
ulus-induced shedding of HB-EGF in Vero-H cells (38), al-
though ADAM9-null mice did not display an overt phenotype,
and cells derived from them shed HB-EGF normally (65). Ad-
ditionally, a dominant negative ADAM9 did not interfere with
HB-EGF cleavage-dependent GPCR transactivation of EGFR
(19), and as described here, ADAM9 did not cleave pro-HB-
EGFecto in vitro (data not shown). Dominant negative
ADAM10 and/or antisense oligonucleotides blocked GPCR-in-
duced HB-EGF shedding and EGFR transactivation, respec-
tively, in COS7 (23) and mucosal epithelial cells (39). However,
whereas ADAM10 cleaved the juxtamembrane stalk of pro-HB-
EGFecto in our studies (Fig. 3), the cleavage site was located
several residues downstream of the C terminus of mature HB-
EGF, closer to the transmembrane domain than is observed
with other EGF family precursors. Because ADAM10 knockout
mice died at embryonic day 9.5 exhibiting multiple defects,
including severely delayed heart development (66), a direct
comparison to the later and more restricted valvulogenesis
defects displayed by HB-EGF knockouts is not possible.
ADAM12 has been linked to the role of HB-EGF in experimen-
tally induced cardiac hypertrophy. A dominant negative
ADAM12 blocked GPCR-induced HB-EGF shedding from car-
diomyocytes, and a novel metalloprotease inhibitor of HB-EGF
shedding bound ADAM12 and also attenuated both HB-EGF
shedding and hypertrophic changes in a mouse model (21). Like
HB-EGF null mice, a significant proportion of mice lacking
ADAM12 die prior to weaning, and fibroblasts from ADAM12-
null mice did not shed HB-EGF in response to TPA (67). How-
ever, cardiac defects were not observed in this model. ADAM19
knockout mice displayed enlarged cardiac valves, replicating at
least part of the HB-EGF-deficient phenotype (68). On the
other hand, cell-based studies using primary fibroblasts from
ADAM19, -10, and -9/12/15 knockout mice indicated that HB-
EGF shedding is not impaired in these cells. Moreover, a bati-
mastat-insensitive activity was also implicated in shedding
(59). Finally, MMP-3 (69) and MMP7/matrilysin (70) have also
been put forth as candidate HB-EGF convertases. Conceivably,
multiple proteases could contribute to HB-EGF shedding in a
cell type- and stimulus-dependent manner.
In contrast to its actions on the HB-EGF and AR precursors
(31), TACE did not enhance the constitutive ectodomain shed-
ding of either BTC or EPR from cotransfected EC-2 cells, and it
did not efficiently cleave the juxtamembrane stalks of either
ectodomain in vitro. Constitutive shedding of BTC and EPR
were metalloprotease-dependent, as TAPI-2 blocked produc-
tion of the soluble media forms (Fig. 2A). However, TACE may
have a role in PMA-stimulated EPR shedding (Fig. 2B). Most
interesting, CHO cells that normally express TACE (25) did not
efficiently release BTC and instead accumulated membrane-
associated forms (Fig. 7B). Our results also confirm the report
from a recent study that secretion of a transfected BTC/alka-
line phosphatase fusion protein was not stimulated by phorbol
esters (50), an observation that distinguishes BTC processing
from that of other EGF family members, including EPR (42).
These observations raise the possibility that pro-BTC is acted
upon by another metalloprotease or instead functions predom-
inantly through juxtacrine actions involving membrane-associ-
ated forms. Unlike TACE-deficient mice, BTC knockout mice
did not display an overt phenotype (14). Identifying the metal-
loprotease(s) responsible for C-terminal cleavage of BTC, EPR,
and EGF will be key to understanding the biology of these
growth factors. Recently, Sahin et al. (59) identified ADAM10
as a BTC sheddase, although we were unable to confirm
ADAM10 cleavage of BTCecto in vitro (data not shown).
Evidence that TACE is a major C-terminal convertase for
some EGF family members (e.g. TGF-, AR, and HB-EGF) but
not others (BTC and EPR) raises the question as to what
structural features are recognized by sheddases. Because the
sequence and length of juxtamembrane stalks of EGF family
precursors (Fig. 5) are not conserved, sheddase action must be
specified by other structural features. For example, substitu-
tion of stalk sequences from normally shed proteins for those of
integral membrane proteins not subject to shedding conferred
constitutive shedding in the latter (71, 72). Moreover, the
length of the stalk may be an important determinant, because
mutagenesis of the TNF precursor (73) or the growth hormone
receptor (74) revealed a minimum stalk length for efficient
processing, presumably reflecting accessibility of the cleavage
site to the relevant metalloprotease. The distance from the
cleavage site to the membrane may be an important determi-
nant of cleavage. Studies of Kit ligand processing in which the
stalk sequence was reiterated revealed that cleavage occurred
only at the most membrane proximal cleavage site (75), con-
sistent with a mechanism specified by distance from the mem-
brane. In contrast, studies of angiotensin-converting enzyme/
CD4 (76) or L-selectin/B7.2 (72) chimeric proteins underscored
the importance of the distal ectodomain as a primary determi-
nant of efficient shedding. Moreover, although they share the
same stalk, the testis angiotensin-converting enzyme isoform
was shed more efficiently (77), presumably due to the presence
of a distal structural motif that was recognized by the process-
ing enzyme (78).
Undoubtedly, the sequence of the cleavage site must impact
shedding efficiency as well. A study of macrophage colony-
stimulating factor shedding indicated that both the scissile
bond sequence and the distance from the membrane deter-
mined cleavage (79). The fact that TACE cleaves TNF  TGF-
  AR/HB-EGF suggests it prefers small apolar amino acids
in the P1 and P1 positions (31). Our present results are in
keeping with these indications, because lengthening the pro-
BTC stalk either directly or by substituting the pro-TGF-
stalk stimulated BTC shedding, whereas the converse manip-
ulations to pro-TGF- reduced TGF- shedding. The effect of
lengthening the pro-BTC stalk was enhanced by simulta-
neously substituting the preferred P2–P2 recognition site of
pro-TGF-. Thus, the combination of stalk length and scissile
bond sequence determines the efficiency of EGF family
shedding.
In addition to cleaving the juxtamembrane stalks of pro-
TGF-, pro-AR, and pro-HB-EGF, TACE also cleaved these
precursors at one or more N-terminal sites. In the case of
pro-TGF-, we previously established that TACE correctly
cleaved the physiologic N-terminal processing site in vitro (31).
Here, we showed that TACE cleaved mouse pro-ARecto in vitro
at a site (99Q2V100) corresponding to one of two N termini
identified for human AR purified from cell culture (53). Human
HB-EGF purified from cell culture also displayed heterogeneous
N termini corresponding to 31R2G32, 62R2D63, 72L2R73, and
73R2V74 (55–58). TACE cleaved mouse HB-EGF in vitro two
residues downstream of 31R2G32 to produce a protein that re-
tained the heparin binding domain. Whether this corresponds to
a bona fide N terminus of the murine protein is presently un-
clear. TACE also cleaved the N-terminal regions of pro-BTC and
pro-EPR (Figs. 2 and 3), albeit less efficiently, thus precluding
identification of the cleavage sites. Most interesting, TACE in-
variably cleaved the N-terminal regions of EGF family precur-
sors more rapidly and with greater efficiency than it cleaved the
stalk regions. This observation agrees with an earlier cell-based
study that revealed more rapid processing of the pro-TGF- N-
terminal site compared with the stalk cleavage site (80).
The possibility that TACE mediates both N- and C-terminal
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cleavage events in the EGF family raises the interesting ques-
tion as to how this membrane-anchored protease cleaves dis-
tant sites separated by the EGF-like motif and, in some cases,
additional sequences. Identifying the mechanism and recogni-
tion elements required for TACE-dependent N-terminal cleav-
age events may provide more insight into the requirements and
relative inefficiency of C-terminal cleavage.
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